(Q41227738)

28 September 2017

1 reference

title

2-chloro-2'-deoxyadenosine: clinical applications in hematology (English)

1 reference

28 September 2017

Delannoy A

1

1 reference

28 September 2017

1 September 1996

1 reference

28 September 2017

1 reference

28 September 2017

10

1 reference

28 September 2017

3

1 reference

28 September 2017

148-166

1 reference

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Clinical and toxicological aspects of the antineoplastic drug cladribine: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Renal handling of 2'-deoxyadenosine and adenosine in humans and mice

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

A phase I study of intermittent infusion cladribine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Low-dose cladribine for symptomatic hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Neurotoxicity of purine analogs: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Marrow suppression produced by repeated doses of cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Cladribine and severe myelotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

1 reference

7 January 2021

High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Care of patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Treatment of advanced chronic lymphocytic leukemia by fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Molecular complete response in a patient with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Treatment of Waldenstrom's Macroglobulinemia with Nucleoside Analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine treatment of low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine and multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine to treat refractory histiocytosis X.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2896%2990022-3

7 January 2021

10.1016/S0268-960X(96)90022-3

Identifiers

DOI

1 reference

28 September 2017

1 reference

PubMed ID

8932828